The U.S. Food and Drug Administration approved Herstal, Belgium-based STX-Med to market Cefaly, the first medical device offering preventative treatment for migraines.
Cefaly is also the first transcutaneous electrical nerve stimulation device authorized for use before the onset of pain.
The device resembles a headband and is worn across the forehead and on top of the ears. It releases an electric current to the skin that reaches the tissue and stimulates branches of the trigeminal nerve, a nerve associated with migraines.
Cefaly is only approved for use for patients at least 18 years old, and should only be used once a day for 20 minutes.
More Articles on FDA Approvals:
Medtronic Receives FDA 510(k) Clearance for Reveal LINQ Insertable Cardiac Monitor
FDA Approves Magellan 6Fr Robotic Catheter
JustRight Surgical Receives FDA 510(k) Clearance for 5mm Surgical Stapler